Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Alpha Teknova, Inc. Common Stock

TKNO

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

Last trade $7.74
Day change -$0.03 (-0.39%)
Day range $7.54 – $7.87
Volume 86,190
Market cap $489M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$488.76M
Price / earnings
—
Price / book
8.18×
Price / sales
10.64×
EV / sales
10.78×
EV / EBITDA
-57.18×

Profitability

Earnings per share
-$0.25
Return on assets
-16.87%
Return on equity
-26.72%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.22×
Current ratio
3.56×
Quick ratio
2.72×
Cash ratio
0.74×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TKNO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$12.7M$12.19M$11.08M$9.98M$10.45M$10.29M$10.28M$9.27M
Cost of revenue$7.88M$7.3M$7.29M$6.74M$7.25M$6.3M$6.79M$7.14M
Gross profit$4.83M$4.89M$3.78M$3.24M$3.21M$3.98M$3.49M$2.13M
Selling, general and administrative$7.16M$6.93M$7.19M$7.04M$6.39M$6.5M$7.13M$6.88M
Research and development$581K$554K$609K$522K$542K$581K$552K$594K
Total operating expenses$8.03M$7.78M$8.08M$7.85M$7.22M$7.37M$7.97M$7.76M
Operating income-$3.21M-$2.89M-$4.3M-$4.61M-$4.02M-$3.39M-$4.48M-$5.63M
Interest expense-$259K-$252K$0-$211K-$190K-$165K$0-$129K
Income before taxes-$3.46M-$3.14M-$4.51M-$4.82M-$4.21M-$3.55M-$4.62M-$5.76M
Income taxes$34K$30K$47K-$62K$79K$19K$22K-$38K
Net income-$3.49M-$3.17M-$4.56M-$4.76M-$4.29M-$3.57M-$4.65M-$5.72M
Net income attributable to common shareholders-$3.49M-$3.17M-$4.56M-$4.76M-$4.29M-$3.57M-$4.65M-$5.72M
EBITDA-$1.62M-$1.3M-$2.72M-$3.03M-$2.43M-$1.8M-$2.9M-$3.98M
Basic earnings per share-$0.06-$0.06-$0.08-$0.09-$0.08-$0.07-$0.09-$0.11
Diluted earnings per share-$0.06-$0.06-$0.08-$0.09-$0.08-$0.07-$0.09-$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?

Alpha Teknova (TKNO) shares rose 5.1% to $6.15 after announcing robust preliminary Q3 2026 financial results with revenues expected between $12.5-$12.7 million. Despite the rally, the stock remains down 34.5% over the past four weeks. The company is expected to post a quarterly loss of $0.06 per share with revenues up 12% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the recent jump may lack sustained momentum.

GlobeNewswire Inc.

Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026

Alpha Teknova (TKNO) announced it will report third quarter 2026 financial results on November 4, 2026, followed by a webcast and conference call at 6:00 p.m. ET. The company, a producer of critical reagents for life sciences, also recently announced a $40 million public offering of common stock.

GlobeNewswire Inc.

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Alpha Teknova (TKNO) announced the pricing of an underwritten public offering of 8 million shares at $5.00 per share, generating $40 million in gross proceeds. The offering is expected to close on October 22, 2026. Teknova intends to use net proceeds for general corporate purposes, including potential debt repayment and strategic acquisitions.

Zacks Investment Research

All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

Alpha Teknova (TKNO) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months with a 5.2% increase in consensus estimates. The upgrade positions the biopharmaceutical reagent maker in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.